096530.KQ Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 mai 2024 @ 08:30):

Stats
Dagens volum	0.00
Gjennomsnittsvolum	330 155
Markedsverdi	1 019.88B
EPS	KRW0 ( 2024-02-15 )
Neste inntjeningsdato	( KRW0 ) 2024-05-10
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW48.52 (0.22%)

Volum Korrelasjon

Lang: -0.05 (neutral)

Kort: 0.16 (neutral)

Signal:(48.155) Neutral

Seegene, Inc. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Seegene, Inc. Korrelasjon - Valuta/Råvare

0.26
( neutral )

0.25
( neutral )

0.17
( neutral )

0.20
( neutral )

0.05
( neutral )

-0.10
( neutral )

Seegene, Inc. Økonomi

Annual	2023
Omsetning:	KRW367.38B
Bruttogevinst:	KRW180.07B (49.02 %)
EPS:	KRW14.19

FY	2023
Omsetning:	KRW367.38B
Bruttogevinst:	KRW180.07B (49.02 %)
EPS:	KRW14.19

FY	2022
Omsetning:	KRW853.56B
Bruttogevinst:	KRW466.15B (54.61 %)
EPS:	KRW3 586.29

Financial Reports:

No articles found.

Seegene, Inc.

Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection products; drug resistance products; Magicplex sepsis real-time test for the detection and identification of sepsis causing pathogens; and meningitis detection products. The company also provides other products for the detection of six SNPs in factor II, factor V, and MTHFR genes; BRAF mutation characteristic for papillary thyroid carcinoma from samples of thyroid tissue, fine needle aspiration biopsy, H&E slides, and paraffin-embedded tissues; Apolipoprotein E genotypes; and BCR/ABL fusion gene from blood and whole bone marrow. In addition, it offers PCR machines; vial cap management systems; nucleic acid extraction systems; automated liquid handling workstations from nucleic acid extraction to PCR setup; and real-time PCR detection systems. Seegene, Inc. was founded in 2000 and is headquartered in Seoul, South Korea.